- Home
- FBRT vs SYRE Comparison
FBRT vs SYRE Comparison
Compare FBRT & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRT
- SYRE
- Stock Information
- Founded
- FBRT 2012
- SYRE 2013
- Country
- FBRT United States
- SYRE United States
- Employees
- FBRT N/A
- SYRE N/A
- Industry
- FBRT Real Estate Investment Trusts
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- FBRT Real Estate
- SYRE Health Care
- Exchange
- FBRT Nasdaq
- SYRE Nasdaq
- Market Cap
- FBRT 919.2M
- SYRE 897.9M
- IPO Year
- FBRT 1985
- SYRE 2016
- Fundamental
- Price
- FBRT $11.50
- SYRE $14.22
- Analyst Decision
- FBRT Strong Buy
- SYRE Buy
- Analyst Count
- FBRT 5
- SYRE 8
- Target Price
- FBRT $15.50
- SYRE $50.00
- AVG Volume (30 Days)
- FBRT 634.9K
- SYRE 859.8K
- Earning Date
- FBRT 04-28-2025
- SYRE 05-08-2025
- Dividend Yield
- FBRT 12.32%
- SYRE N/A
- EPS Growth
- FBRT N/A
- SYRE N/A
- EPS
- FBRT 0.82
- SYRE N/A
- Revenue
- FBRT $174,755,000.00
- SYRE N/A
- Revenue This Year
- FBRT $20.39
- SYRE N/A
- Revenue Next Year
- FBRT $1.45
- SYRE N/A
- P/E Ratio
- FBRT $14.07
- SYRE N/A
- Revenue Growth
- FBRT N/A
- SYRE N/A
- 52 Week Low
- FBRT $10.50
- SYRE $10.91
- 52 Week High
- FBRT $14.12
- SYRE $40.49
- Technical
- Relative Strength Index (RSI)
- FBRT 41.94
- SYRE 45.86
- Support Level
- FBRT $10.98
- SYRE $12.04
- Resistance Level
- FBRT $11.40
- SYRE $13.29
- Average True Range (ATR)
- FBRT 0.51
- SYRE 1.24
- MACD
- FBRT 0.03
- SYRE 0.32
- Stochastic Oscillator
- FBRT 46.51
- SYRE 80.54
About FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.